Developing an insulin patch pump with open-protocol communication
Imagine an automated insulin delivery system that is able to connect with other devices seamlessly. A state-of-the-art, tubeless technology that provides continuous insulin therapy, operates on its own platform and publishes its own communication protocol.
Thanks to a new partnership between JDRF and medical technology company, SFC Fluidics, Inc., this functional insulin patch pump may soon revolutionize the lives of people living with type 1 diabetes (T1D) and become the highly sought technology among patients with the disease.
A two-year funding commitment from JDRF will enable SFC Fluidics to foster the development and delivery of the interoperable insulin pump. The new technology enables flawless, secure connectivity with other devices (e.g., Bluetooth) such as continuous glucose monitors and other third-party automated insulin delivery technologies (e.g., solutions by the do-it-yourself community).
For more than a decade, JDRF has played a leadership role in accelerating the expansion and commercialization of artificial pancreas (AP) systems that program insulin delivery. In 2017, JDRF launched its Open-Protocol Automated Insulin Delivery (AID) Systems Initiative and worked with key stakeholders to identify the regulatory and liability implications of an open-protocol AID ecosystem.
This new solution is expected to not only provide a greater range of future treatment options for people living with T1D, but to also increase the adoption of these cutting-edge, life-enhancing technologies.
For more informative articles on health and type 1 diabetes, visit our JDRF Blog.